Fig. 3

Effect of glycolysis inhibition in macrophage phagocytosis and phenotype. Fresh elicited peritoneal macrophages were treated with different concentrations of 2-DG for 1 h. Phagocytosis was measured using the pHrodo S.aureus bioparticles kit and cell viability by AlamarBlue® assay. The expression of F4/80, CD16/32, and CD64 was evaluated by flow cytometry. a ECAR in control and 2-DG treated macrophages. b Phagocytosis of pHrodo S.aureus bioparticles in control and 2-DG treated macrophages. c Macrophage viability following 2-DG treatment. d Representative flow cytometry data showing the expression levels of F4/80, CD16/32 and CD64 in control and 2-DG treated macrophages. e The percentage of F4/80⁺, CD16/32⁺ and CD64⁺ cells in control un-treated (UT) and 2-DG treated macrophages. Mean ± SEM, N = 4 mice. *p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA, followed by Dunnett’s test